Online citations, reference lists, and bibliographies.
← Back to Search

Fifteen Years In The Evaluation Of Extrapleural Pneumonectomy: Lessons To Be Learned.

T. Treasure, F. Macbeth
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
From 2001 to 2010, a total of 447 patients were recorded in Brigham and Women’s Hospital (BWH) International MesotheliomaProgramPatient DataRegistryashavinghadextrapleural pneumonectomy (EPP). Patterns of recurrence among 169 (38%) who had undergone initial EPP are reported. The remaining 62% of patients, treated initially with chemotherapy, were excluded as ‘‘a distinct cohort with poorer prognosis.’’ Median survival was 15 months for the EPP-first patients, and evidently shorter 1 for the remaining 62%.
This paper references
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
Ten traps for the unwary in surgical series: a case study in mesothelioma reports.
T. Treasure (2007)
Surgical resection of mesothelioma: an evidence-free practice
Y. Lee (2014)
The true cost of pharmacological disease prevention
T. Järvinen (2011)
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial
R. Rintoul (2014)
Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position
A. Datta (2013)
So Much for That
Lionel Shriver (2001)
Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma.
M. Utley (2010)
Radical surgery for mesothelioma
T. Treasure (2004)
Pulmonary metastasectomy: are observational studies sufficient evidence for effectiveness?
F. Fiorentino (2013)
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes
L. Lévesque (2010)
MARS: a sense of perspective and an inconvenient truth.
T. Treasure (2013)
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
E. Baldini (2015)
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
T. Treasure (2009)
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
O. Rena (2012)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
When are randomised trials unnecessary? Picking signal from noise
P. Glasziou (2007)
Contemporary management of malignant pleural mesothelioma.
E. Butchart (1999)
Surgery for malignant pleural mesothelioma: why we need controlled trials.
T. Treasure (2014)
The European mesothelioma epidemic
J. Peto (1999)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar